OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Down 50.1% in February

OSR Holdings, Inc. (NASDAQ:OSRH) saw a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 226,774 shares, a decrease of 50.1% from the January 29th total of 454,339 shares. Approximately 2.2% of the shares of the company are short sold. Based on an average daily volume of 616,711 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily volume of 616,711 shares, the days-to-cover ratio is presently 0.4 days. Approximately 2.2% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

OSR Stock Down 4.8%

OSR stock opened at $0.42 on Friday. OSR has a 52-week low of $0.39 and a 52-week high of $4.33. The firm has a market capitalization of $10.78 million, a price-to-earnings ratio of -0.38 and a beta of 1.41. The firm has a 50-day moving average price of $0.59 and a two-hundred day moving average price of $0.62.

Hedge Funds Weigh In On OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP bought a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent reporting period. 55.30% of the stock is owned by institutional investors and hedge funds.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.